News Column

New Findings from Institute for Biology Research in Enzymes and Coenzymes Provides New Insights

January 30, 2014



By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Research findings on Enzymes and Coenzymes are discussed in a new report. According to news reporting originating in Grenoble, France, by NewsRx journalists, research stated, "Acetylcholinesterase is the physiological target for acute toxicity of nerve agents. Attempts to protect acetylcholinesterase from phosphylation by nerve agents, is currently achieved by reversible inhibitors that transiently mask the enzyme active site."

The news reporters obtained a quote from the research from Institute for Biology Research, "This approach either protects only peripheral acetylcholinesterase or may cause side effects. Thus, an alternative strategy consists in scavenging nerve agents in the bloodstream before they can reach acetylcholinesterase. Pre- or post-exposure administration of bioscavengers, enzymes that neutralize and detoxify organophosphorus molecules, is one of the major developments of new medical counter-measures. These enzymes act either as stoichiometric or catalytic bioscavengers. Human butyrylcholinesterase is the leading stoichiometric bioscavenger. Current efforts are devoted to its mass production with care to pharmacokinetic properties of the final product for extended lifetime. Development of specific reactivators of phosphylated butyrylcholinesterase, or variants with spontaneous reactivation activity is also envisioned for rapid in situ regeneration of the scavenger. Human paraoxonase 1 is the leading catalytic bioscavenger under development. Research efforts focus on improving its catalytic efficiency toward the most toxic isomers of nerve agents, by means of directed evolution-based strategies. Human prolidase appears to be another promising human enzyme. Other non-human efficient enzymes like bacterial phosphotriesterases or squid diisopropylfluorophosphatase are also considered though their intrinsic immunogenic properties remain challenging for use in humans. Encapsulation, PEGylation and other modifications are possible solutions to address this problem as well as that of their limited lifetime."

According to the news reporters, the research concluded: "Finally, gene therapy for in situ generation and delivery of bioscavengers is for the far future, but its proof of concept has been established."

For more information on this research see: Progress in the development of enzyme-based nerve agent bioscavengers. Chemico-Biological Interactions, 2013;206(3):536-544. Chemico-Biological Interactions can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland. (Elsevier - www.elsevier.com; Chemico-Biological Interactions - www.elsevier.com/wps/product/cws_home/505510)

Our news correspondents report that additional information may be obtained by contacting F. Nachon, CNRS CEA UJF, Inst Biol Struct JP Ebel, UMR 5075, F-38042 Grenoble 9, France. Additional authors for this research include X. Brazzolotto, M. Trovaslet and P. Masson (see also Enzymes and Coenzymes).

Keywords for this news article include: Biotechnology, France, Europe, Grenoble, Hydrolases, Gene Therapy, Bioengineering, Biogenic Amines, Acetylcholinesterase, Enzymes and Coenzymes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Gene Therapy Weekly


Story Tools